Controlled trials in hepatitis B virus-related decompensate liver cirrhosis: peripheral blood monocyte transplant versus granulocyte–colony-stimulating factor mobilization therapy

Han, Ying; Li, Yan; Han, Guohong; Zhou, Xin; Hong, Liu; Yin, Zhihua; Zhang, X; Wang, S; Wang, J; Sun, An-Hua; Liu, Zhiguo; Xie, Hui; Wu, Kaichun; Ding, Jie; Fan, Daiming

doi:10.1080/14653240802129901

Cited by 51 publications

(29 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…hematopoietic cells harvested from a peripheral vein, avoiding the need for invasive procedures. Furthermore, several routes of cell administration have been investigated, included peripheral veins, the hepatic artery, and the portal vein [45][46][47][48][49][50][51][52][53][54]. In a randomized control study, Spahr et al reported that there were no significant differences in treatment outcomes when using autologous BMNCs harvested after G-CSF infusion through the hepatic artery, although several other randomized studies have shown favorable results, suggesting the usefulness of these therapies [50].…”

Section: Autologous Bone Marrow Cell Injection Therapy and Related Trmentioning

confidence: 99%

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Terai

Tsuchiya

2016

J Gastroenterol

View full text Add to dashboard Cite

The treatment of liver cirrhosis is currently being standardized and developed specifically to reduce activation of hepatic stellate cells (HSCs), inhibit fibrosis, increase degradation of matrix components, and reduce activated myofibroblasts. Cell therapy can be applied in the treatment of liver cirrhosis; however, the characteristic features of this therapy differ from those of other treatments because of the involvement of a living body origin and production of multiple cytokines, chemokines, matrix metalloproteinases (MMPs), and growth factors. Thus, cell therapies can potentially have multiple effects on the damaged liver, including alleviating liver cirrhosis and stimulating liver regeneration with affecting the host cells. Cell therapies initially involved autologous bone marrow cell infusion, and have recently developed to include the use of specific cells such as mesenchymal stem cells and macrophages. The associated molecular mechanisms, routes of administration, possibility of allogeneic cell therapy, and host conditions appropriate for cell therapies are now being extensively analyzed. In this review, we summarize the status and future prospects of cell therapy for liver cirrhosis.

show abstract

Section: Autologous Bone Marrow Cell Injection Therapy and Related Trmentioning

confidence: 99%

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Terai

Tsuchiya

2016

J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…A report by Han et al [23] also described G-CSF administration for HBV-related decompensated LC. In that study, the administration of peripheral blood MNCs induced by G-CSF led to significant improvements in serum albumin and the Child-Pugh score at 6 months after treatment, as compared to findings in patients treated with G-CSF mobilization alone for 4 days.…”

Section: Granulocyte-colony Stimulation Factor Induction Therapymentioning

confidence: 89%

Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future stem cell therapy

et al. 2012

View full text Add to dashboard Cite

Liver cirrhosis patients generally progress to liver failure. To cure this progressive disease, we developed a novel cell therapy using bone marrow cells; autologous bone marrow cell infusion (ABMi) therapy. We previously described the possible action mechanism of ABMi therapy in the cirrhotic liver, and showed the timeline and results of clinical studies of ABMi therapy. We have also carried out other clinical studies using bone marrow cells and granulocyte colony-stimulating factor. Here, we report a new randomized clinical trial to evaluate the effects of ABMi therapy. However, ABMi therapy may not be possible in patients who are unable to undergo general anesthesia; therefore, we have started to develop a next-generation stem cell therapy using cultured mesenchymal stem cells.

show abstract

“…When compared to granulocyte-colony-stimulating factor mobilization therapy alone, peripheral blood monocyte transplant therapy offered a significant improvement in liver function as measured by albumin levels and Child-Pugh scores [113]. Another study found that after intraparenchymal autologous mesenchymal bone marrow-derived stem cell transplantation in hepatitis C patients, the liver showed structural improvement as evidenced by its decreased extracellular matrix protein count on biopsy [114].…”

Section: Potential Applications Of Stem Cells In Liver Diseasesmentioning

confidence: 99%

Stem Cell Therapies for Treatment of Liver Disease

et al. 2016

View full text Add to dashboard Cite

Cell therapy is an emerging form of treatment for several liver diseases, but is limited by the availability of donor livers. Stem cells hold promise as an alternative to the use of primary hepatocytes. We performed an exhaustive review of the literature, with a focus on the latest studies involving the use of stem cells for the treatment of liver disease. Stem cells can be harvested from a number of sources, or can be generated from somatic cells to create induced pluripotent stem cells (iPSCs). Different cell lines have been used experimentally to support liver function and treat inherited metabolic disorders, acute liver failure, cirrhosis, liver cancer, and small-for-size liver transplantations. Cell-based therapeutics may involve gene therapy, cell transplantation, bioartificial liver devices, or bioengineered organs. Research in this field is still very active. Stem cell therapy may, in the future, be used as a bridge to either liver transplantation or endogenous liver regeneration, but efficient differentiation and production protocols must be developed and safety must be demonstrated before it can be applied to clinical practice.

show abstract

Controlled trials in hepatitis B virus-related decompensate liver cirrhosis: peripheral blood monocyte transplant versus granulocyte–colony-stimulating factor mobilization therapy

Cited by 51 publications

References 22 publications

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis

Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future stem cell therapy

Stem Cell Therapies for Treatment of Liver Disease

Contact Info

Product

Resources

About